Seroepidemiologic methods to identify hotspots of trachoma and predict future infection
Project Number7R03AI147128-02
Former Number1R03AI147128-01
Contact PI/Project LeaderARNOLD, BENJAMIN F
Awardee OrganizationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO
Description
Abstract Text
Project Summary / Abstract
Background: Trachoma, caused by ocular infection with Chlamydia trachomatis, is the leading cause of
infectious blindness worldwide and has been targeted for global elimination as a public health problem by
2020. This goal will be achieved in many countries, but some regions in Ethiopia maintain persistently high
levels of infection despite >10 years of intensive control activities. A small proportion of the population likely
harbors the majority of trachoma infections, with foci of infection (“hotspots”) at or below the village scale; the
operational challenge is accurately predicting where they are with existing data. Advances in machine learning
and spatial data science have demonstrated marked improvements in the spatial resolution of predictions for
diseases like malaria. Among available biomarkers of trachoma, IgG antibody responses in children could
enable more accurate predictions because they integrate exposure over time and reflect recent transmission.
Aims: The principal aims of this study are to evaluate whether antibody measurements can identify stable
hotspots of trachoma infection, and whether a novel machine learning approach can accurately predict village-
level trachoma infection forward in time (up to 3 years). We hypothesize that infection will be concentrated in
the population and that hotspots of infection will be at the village level. We further hypothesize that antibody
measurements in young children will provide a stable source of information about trachoma transmission that
will enable us to accurately predict villages with high levels of future C. trachomatis infection.
Methods: To test our hypotheses, we will draw on measurements from a well characterized population across
40 villages enrolled in a NIH-funded cluster randomized trial in Ethiopia’s Amhara Region (U10-EY023939).
The three-year trial is designed to measure the effect of improved water, sanitation, and handwashing (WASH)
on trachoma infection in the absence of azithromycin treatment. The trial has collected clinical and biomarker
measurements from approximately 2,400 children ages 0-9 years at enrollment and in annual visits over 3
years. We will characterize the spatial scale of transmission using the !-statistic, which equals the relative risk
of infection within different distances of cases. We will use a permutation-based, spatial scan statistic to
identify hotspots using IgG antibody and PCR measures in each year, and will determine if they are stable over
time. Using geospatial ensemble machine learning, we will predict trachoma seroprevalence as a function of
remotely sensed, geospatial information and limited enrollment characteristics. We will rank order villages by
predicted seroprevalence, and will assess the proportion of PCR C. trachomatis infections in top-ranked
villages 1, 2, and 3 years later. We will repeat the analysis using predicted clinical symptoms as a comparator.
The development of methods to make accurate, fine-scale predictions of future C. trachomatis infection will lay
the groundwork for a future adaptive randomized trial that preferentially allocates more intensive intervention to
villages predicted at enrollment to have high future levels of infection.
Public Health Relevance Statement
Project Narrative / Lay Language Description
Trachoma is the leading cause of infectious blindness worldwide and has been targeted for global elimination
as a public health problem by 2020. Trachoma control programs target and monitor activities at the level of
districts, but it is likely that infection hotspots are concentrated at much smaller scales and could be missed in
district-level averages. We propose to combine antibody-based measures of exposure with state-of-the-art
machine learning to develop predictions of trachoma infection at the scale of individual villages in the Amhara
region of Ethiopia, which would represent a substantial increase in the resolution of information available to
guide control and monitoring efforts.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
094878337
UEI
KMH5K9V7S518
Project Start Date
09-July-2019
Project End Date
30-June-2021
Budget Start Date
01-September-2019
Budget End Date
30-June-2020
Project Funding Information for 2019
Total Funding
$85,723
Direct Costs
$53,410
Indirect Costs
$32,313
Year
Funding IC
FY Total Cost by IC
2019
National Institute of Allergy and Infectious Diseases
$85,723
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7R03AI147128-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7R03AI147128-02
Patents
No Patents information available for 7R03AI147128-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7R03AI147128-02
Clinical Studies
No Clinical Studies information available for 7R03AI147128-02
News and More
Related News Releases
No news release information available for 7R03AI147128-02
History
No Historical information available for 7R03AI147128-02
Similar Projects
No Similar Projects information available for 7R03AI147128-02